Quantcast
Last updated on April 24, 2014 at 11:52 EDT

Latest Digene Stories

2014-04-16 08:30:31

GERMANTOWN, Md., April 16, 2014 /PRNewswire/ -- -- Investment of $10 million in Germantown and Frederick campuses brings QIAGEN's total recent commitment in Maryland to $50 million -- Germantown campus becomes state-of-the-art research, manufacturing and office site for Molecular Diagnostics with consolidation of activities from Gaithersburg site -- Germantown site passes FDA pre-approval inspection to manufacture digene HC2 HPV Test --...

2014-02-26 04:21:32

KOLKATA, India, February 26, 2014 /PRNewswire/ -- - The careHPV(TM) Test is the first HPV diagnostic designed for regions with limited healthcare infrastructure, complementing QIAGEN's market-leading digene HC2 HPV Test - Commercial launch of careHPV Test in India enables high-quality screening for prevention of cervical cancer among women in low-resource areas - The careHPV Test plays an important role in QIAGEN's...

2014-01-29 16:28:20

VENLO, The Netherlands, January 29, 2014 /PRNewswire/ -- - Achieved 2013 targets: Adjusted net sales $1.31 billion (+5% CER), growth in all regions and customer classes; adjusted operating income $355.8 million; adjusted EPS $1.14 - Q4 2013 results: Adjusted net sales $362.6 million (+5% CER); adjusted operating income $106.3 million; adjusted EPS $0.36 - Ambition to build on 2013 progress to further accelerate innovation and...

2013-07-30 16:25:03

VENLO, The Netherlands, July 30, 2013 /PRNewswire/ -- - Q2 2013 results: Adjusted net sales of $316.4 million (+3% CER) on growth in all regions; adjusted operating income of $83.4 million; adjusted diluted EPS of $0.27 per share - Making progress to accelerate innovation and growth amid challenging conditions - Building momentum in Personalized Healthcare with FDA approval of therascreen EGFR companion...

2013-07-08 08:26:57

NEW YORK, July 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Joseph Slattery has been appointed to the Exosome Diagnostics Board of Directors. Mr. Slattery, 48, brings significant finance and diagnostic industry experience to the Company. He currently serves as Chief Financial Officer and Executive Vice President of Baxano Surgical, Inc. (formerly TranS1 Inc.), a...

2013-06-06 16:27:02

GERMANTOWN, Maryland, and HILDEN, Germany, June 6, 2013 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has made public on June 6 a new non-exclusive agreement to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN has been informed that its HPV-related products will...

2013-04-29 16:30:40

VENLO, The Netherlands, April 29, 2013 /PRNewswire/ -- - Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS at $0.23 per share; free cash flow of $30 million - Progress toward accelerating innovation and growth in 2013: - Molecular Diagnostics (+11% CER) and Applied Testing (+5% CER) deliver solid results, more than offset weak market...

2012-11-28 16:25:39

SHENZEN, China and HILDEN, Germany, November 28, 2012 /PRNewswire/ -- - Commercial launch of careHPV in China and other emerging markets will enable high-quality screening for prevention of cervical cancer - "Country of Origin" approval key for dissemination, other countries are able to use this as a basis for registration - careHPV is the first HPV test designed for areas with limited healthcare infrastructure,...

2012-05-03 10:26:24

HILDEN, Germany and GERMANTOWN, Maryland, May 3, 2012 /PRNewswire/ -- - QIAGEN expands Point of Need portfolio with unique AmniSureassay to detect rupture of fetal membranes (ROM) - checked in up to 30% of U.S. pregnancies - Novel FDA-cleared test is highly synergistic with QIAGEN's clinical sales channels QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of AmniSure International LLC...

2012-04-25 10:25:23

VENLO, The Netherlands, April 25, 2012 /PRNewswire/ -- - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjusted diluted EPS grows to $0.23 per share - Making progress on strategic initiatives to drive innovation and growth: - Driving platform success: On track to exceed more than 750 installed QIAsymphony systems by end-2012 as global rollout continues - Adding content:...